Orchestra BioMed Holdings, Inc. (OBIO) Earnings History
Annual and quarterly earnings data from 2020 to 2025
Loading earnings history...
OBIO EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
OBIO Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 99.4% | -154.7% | -158.2% |
| 2024 | 92.3% | -2437.5% | -2313.3% |
| 2023 | 93.3% | -1866.2% | -1779.7% |
| 2022 | 90.9% | -924.3% | -951.3% |
| 2021 | - | - | - |
Download Data
Export OBIO earnings history in CSV or JSON format
Free sign-in required to download data
Orchestra BioMed Holdings, Inc. (OBIO) Earnings Overview
As of May 8, 2026, Orchestra BioMed Holdings, Inc. (OBIO) reported trailing twelve-month net income of -$53M, reflecting +33.1% year-over-year growth. The company earned $-1.38 per diluted share over the past four quarters, with a net profit margin of -158.2%.
Looking at the long-term picture, OBIO's historical earnings data spans multiple years. The company achieved its highest annual net income of -$21M in fiscal 2020.
Orchestra BioMed Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including NVCR (-$173M net income, -20.8% margin), XTNT ($2M net income, -14.0% margin), BSX ($2.89B net income, 14.4% margin), OBIO has room to improve margins relative to the peer group. Compare OBIO vs NVCR →
OBIO Earnings vs Peers
Earnings metrics vs comparable public companies
OBIO Historical Earnings Data (2020–2025)
6 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$53M | +13.2% | -$52M | $-1.11 | -158.2% | -154.7% |
| 2024 | -$61M | -24.2% | -$64M | $-1.66 | -2313.3% | -2437.5% |
| 2023 | -$49M | -46.2% | -$52M | $-1.48 | -1779.7% | -1866.2% |
| 2022 | -$34M | -46.0% | -$33M | $-1.32 | -951.3% | -924.3% |
| 2021 | -$23M | -7.8% | -$22M | $-0.02 | - | - |
| 2020 | -$21M | - | -$19M | $-0.01 | -374.5% | -328.8% |
See OBIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs OBIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare OBIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonOBIO — Frequently Asked Questions
Quick answers to the most common questions about buying OBIO stock.
Is OBIO growing earnings?
OBIO EPS is $-1.38, with earnings growth accelerating to +33.1%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-53M.
What are OBIO's profit margins?
Orchestra BioMed Holdings, Inc. net margin is -158.2%, with operating margin at -154.7%. Below-average margins reflect competitive or cost pressures.
How consistent are OBIO's earnings?
OBIO earnings data spans 2020-2025. The accelerating earnings trend is +33.1% YoY. Historical data enables comparison across business cycles.